Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.63 |
| ▸ | KDR | P35968 | 19/20 | 0.63 |
| ▸ | IGF1R | P08069 | 18/20 | 0.63 |
| ▸ | MST1R | Q04912 | 1/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471835 | 0.84 | AXL (0.61) | METKDRIGF1RAXL | |
| SCHEMBL1472349 | 0.83 | AXL (0.60) | METKDRIGF1RMST1RAXL | |
| SCHEMBL199597 | 0.82 | MET (0.69) | METKDRIGF1RMST1R | |
| SCHEMBL1472566 | 0.81 | AXL (0.58) | METKDRIGF1RAXL | |
| SCHEMBL3227406 | 0.81 | KDR (0.73) | METKDRAXL | |
| SCHEMBL199498 | 0.81 | MET (0.69) | METKDRIGF1RMST1R | |
| SCHEMBL3236542 | 0.79 | KDR (0.72) | METKDRMST1RAXL | |
| SCHEMBL1471768 | 0.79 | AXL (0.55) | METKDRIGF1RAXL | |
| SCHEMBL198617 | 0.79 | MET (0.73) | METKDRIGF1R | |
| SCHEMBL3239037 | 0.78 | MEN1 (0.51) | KDRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | claimed |
| US-20110294837-A1 | Aurora Kinase Modulators and Methods of Use | AMGEN INC. | 2011-12-01 | — | — | US | claimed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | claimed |
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20110294837-A1 | Aurora Kinase Modulators and Methods of Use | AMGEN INC. | 2011-12-01 | — | — | US | disclosed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294837-A1 | Aurora Kinase Modulators and Methods of Use | AURKC, AURKA, CDK1 | MET 427/4885KDR 566/4885IGF1R 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.